MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis

Company Overview

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $1.71 to $2.25
• 50-Day Range: $1.05 to $2.20
• 52-Week Range: $0.51 to $6.40
• Volume: 3.21 million shs
• Average Volume: 2.28 million shs
• Market Capitalization: $28.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

MIRA Pharmaceuticals Stock Analysis - MarketRank™

MIRA Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 366th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

MIRA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MIRA Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MIRA Pharmaceuticals is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MIRA Pharmaceuticals is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MIRA Pharmaceuticals has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.44% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently decreased by 22.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MIRA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

MIRA Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.44% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently decreased by 22.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.38

News Sentiment

MIRA Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MIRA Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

16 people have searched for MIRA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

5 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.65% of the stock of MIRA Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.

MIRA Stock Analysis - Frequently Asked Questions

How have MIRA shares performed this year?

MIRA Pharmaceuticals' stock was trading at $1.05 at the beginning of the year. Since then, MIRA stock has increased by 81.0% and is now trading at $1.90.
View the best growth stocks for 2024 here.

How were MIRA Pharmaceuticals' earnings last quarter?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01.

When did MIRA Pharmaceuticals IPO?

MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Thursday, August 3rd 2023. The company issued 1,275,000 shares at a price of $7.00 per share.

Who are MIRA Pharmaceuticals' major shareholders?

MIRA Pharmaceuticals' top institutional investors include Cross Staff Investments Inc (2.48%) and Suncoast Equity Management (0.61%). Insiders that own company stock include George Cappy, Brian Patrick Mcnulty and Erez Aminov.
View institutional ownership trends.

How do I buy shares of MIRA Pharmaceuticals?

Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of MIRA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/01/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIRA
• Previous Symbol: NASDAQ:MIRA
• CUSIP: N/A
• CIK: 1904286
• Web: mirapharmaceuticals.com
• Phone: 737-289-0835
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +636.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,980,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -286.24%
• Return on Assets: -246.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 6.33

Miscellaneous

• Outstanding Shares: 14,780,000
• Free Float: 13,798,000
• Market Cap: $28.08 million
• Optionable: Not Optionable
• Beta: 4.20